1. Home
  2. GERN vs EYE Comparison

GERN vs EYE Comparison

Compare GERN & EYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GERN
  • EYE
  • Stock Information
  • Founded
  • GERN 1990
  • EYE 1990
  • Country
  • GERN United States
  • EYE United States
  • Employees
  • GERN N/A
  • EYE N/A
  • Industry
  • GERN Biotechnology: Pharmaceutical Preparations
  • EYE Ophthalmic Goods
  • Sector
  • GERN Health Care
  • EYE Health Care
  • Exchange
  • GERN Nasdaq
  • EYE Nasdaq
  • Market Cap
  • GERN 840.7M
  • EYE 900.5M
  • IPO Year
  • GERN 1996
  • EYE 2017
  • Fundamental
  • Price
  • GERN $1.18
  • EYE $17.17
  • Analyst Decision
  • GERN Buy
  • EYE Buy
  • Analyst Count
  • GERN 9
  • EYE 7
  • Target Price
  • GERN $5.13
  • EYE $17.14
  • AVG Volume (30 Days)
  • GERN 11.5M
  • EYE 2.8M
  • Earning Date
  • GERN 05-07-2025
  • EYE 05-07-2025
  • Dividend Yield
  • GERN N/A
  • EYE N/A
  • EPS Growth
  • GERN N/A
  • EYE N/A
  • EPS
  • GERN N/A
  • EYE N/A
  • Revenue
  • GERN $116,293,000.00
  • EYE $1,850,850,000.00
  • Revenue This Year
  • GERN $194.54
  • EYE $6.62
  • Revenue Next Year
  • GERN $56.51
  • EYE $2.62
  • P/E Ratio
  • GERN N/A
  • EYE N/A
  • Revenue Growth
  • GERN 22264.04
  • EYE 4.31
  • 52 Week Low
  • GERN $1.17
  • EYE $9.56
  • 52 Week High
  • GERN $5.34
  • EYE $19.49
  • Technical
  • Relative Strength Index (RSI)
  • GERN 32.46
  • EYE 84.04
  • Support Level
  • GERN $1.34
  • EYE $12.98
  • Resistance Level
  • GERN $1.44
  • EYE $12.51
  • Average True Range (ATR)
  • GERN 0.10
  • EYE 0.63
  • MACD
  • GERN 0.00
  • EYE 0.56
  • Stochastic Oscillator
  • GERN 3.23
  • EYE 98.74

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

About EYE National Vision Holdings Inc.

National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.

Share on Social Networks: